Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections - PubMed (original) (raw)
Review
Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections
Andrew Hemphill et al. Expert Opin Pharmacother. 2006 May.
Abstract
Colonisation of the gastrointestinal tract by anaerobic bacteria, protozoa, trematodes, cestodes and/or nematodes and other infectious pathogens, including viruses, represents a major cause of morbidity and mortality in Africa, South America and southeast Asia, as well as other parts of the world. Nitazoxanide is a member of the thiazolide class of drugs with a documented broad spectrum of activity against parasites and anaerobic bacteria. Moreover, the drug has recently been reported to have a profound activity against hepatitis C virus infection. In addition, nitazoxanide exhibits anti-inflammatory properties, which have prompted clinical investigations for its use in Crohn's disease. Studies with nitazoxanide derivatives have determined that there must be significantly different mechanisms of action acting on intracellular versus extracellular pathogens. An impressive number of clinical studies have shown that the drug has an excellent bioavailability in the gastrointestinal tract, is fast acting and highly effective against gastrointestinal bacteria, protozoa and helminthes. A recent Phase II study has demonstrated viral response (hepatitis C) to monotherapy, with a low toxicity and an excellent safety profile over 24 weeks of treatment. Pre-clinical studies have indicated that there is a potential for application of this drug against other diseases, not primarily affecting the liver or the gastrointestinal tract.
Similar articles
- Nitazoxanide: a review of its use in the treatment of gastrointestinal infections.
Anderson VR, Curran MP. Anderson VR, et al. Drugs. 2007;67(13):1947-67. doi: 10.2165/00003495-200767130-00015. Drugs. 2007. PMID: 17722965 Review. - Update on Nitazoxanide: A Multifunctional Chemotherapeutic Agent.
Shakya A, Bhat HR, Ghosh SK. Shakya A, et al. Curr Drug Discov Technol. 2018;15(3):201-213. doi: 10.2174/1570163814666170727130003. Curr Drug Discov Technol. 2018. PMID: 28748751 Review. - Nitazoxanide: clinical studies of a broad-spectrum anti-infective agent.
Aslam S, Musher DM. Aslam S, et al. Future Microbiol. 2007 Dec;2(6):583-90. doi: 10.2217/17460913.2.6.583. Future Microbiol. 2007. PMID: 18041899 - Nitazoxanide: a new thiazolide antiparasitic agent.
Fox LM, Saravolatz LD. Fox LM, et al. Clin Infect Dis. 2005 Apr 15;40(8):1173-80. doi: 10.1086/428839. Epub 2005 Mar 14. Clin Infect Dis. 2005. PMID: 15791519 - Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs.
Stachulski AV, Swift K, Cooper M, Reynolds S, Norton D, Slonecker SD, Rossignol JF. Stachulski AV, et al. Eur J Med Chem. 2017 Jan 27;126:154-159. doi: 10.1016/j.ejmech.2016.09.080. Epub 2016 Sep 26. Eur J Med Chem. 2017. PMID: 27750149 Free PMC article.
Cited by
- Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.
Tsutsumi LS, Owusu YB, Hurdle JG, Sun D. Tsutsumi LS, et al. Curr Top Med Chem. 2014;14(1):152-75. doi: 10.2174/1568026613666131113154753. Curr Top Med Chem. 2014. PMID: 24236721 Free PMC article. Review. - The discovery of medicines for rare diseases.
Swinney DC, Xia S. Swinney DC, et al. Future Med Chem. 2014 Jun;6(9):987-1002. doi: 10.4155/fmc.14.65. Future Med Chem. 2014. PMID: 25068983 Free PMC article. - Protein Kinase R in Bacterial Infections: Friend or Foe?
Smyth R, Sun J. Smyth R, et al. Front Immunol. 2021 Jul 8;12:702142. doi: 10.3389/fimmu.2021.702142. eCollection 2021. Front Immunol. 2021. PMID: 34305942 Free PMC article. Review. - Comparative characterisation of two nitroreductases from Giardia lamblia as potential activators of nitro compounds.
Müller J, Rout S, Leitsch D, Vaithilingam J, Hehl A, Müller N. Müller J, et al. Int J Parasitol Drugs Drug Resist. 2015 Mar 25;5(2):37-43. doi: 10.1016/j.ijpddr.2015.03.001. eCollection 2015 Aug. Int J Parasitol Drugs Drug Resist. 2015. PMID: 27099829 Free PMC article. - Systemic efficacy on Cryptosporidium parvum infection of aminoxanide (RM-5061), a new amino-acid ester thiazolide prodrug of tizoxanide.
Diawara EH, François A, Stachulski AV, Razakandrainibe R, Costa D, Favennec L, Rossignol JF, Gargala G. Diawara EH, et al. Parasitology. 2021 Jul;148(8):975-984. doi: 10.1017/S0031182021000524. Epub 2021 Mar 29. Parasitology. 2021. PMID: 33775260 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources